Feasibility Study of Caregiver-Assist Strategy Training
Launched by TAIPEI MEDICAL UNIVERSITY · Dec 18, 2024
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Caregiver-Assist Strategy Training (CaST) study, is exploring a new way to help people who have had a stroke improve their daily activities. The main goal is to see if the CaST program is acceptable and beneficial for stroke survivors who have some difficulty with daily tasks. Researchers will compare this program to a standard education program to determine how effective CaST is in helping participants regain their functional abilities.
To participate, individuals should be aged between 65 and 74, have experienced an ischemic or hemorrhagic stroke (which are two types of strokes), and have a caregiver who can help them. Participants will attend 10 sessions of either the CaST program or the education program, meeting 1 to 2 times a week. They will be evaluated at different points: before starting, right after completing the program, and again at 3 and 6 months later. Additionally, each participant will have a conversation with researchers after their sessions to share their experiences. This trial is currently recruiting participants and aims to make a positive impact on the lives of stroke survivors and their caregivers.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Being willing to provide informed consent
- • Diagnosis with ischemic and/or hemorrhagic stroke
- • Modified Rankin Scale (mRS) ranges from 2 to 4
- • Rehabilitation frequency less than 3 days per week
- • Having a healthy caregiver
- Exclusion Criteria:
- • Undergoing palliative care
- • Major diseases or severe conditions influencing study participation, such as global aphasia, dementia, multiple organ failure, immobilization due to fracture, etc Moderate post-stroke cognitive impairment, with Montreal Cognitive Assessment score \<22
- • Pre-stroke mRS \> 1
- • Participating in other interventional study concurrently.
About Taipei Medical University
Taipei Medical University (TMU) is a leading educational and research institution located in Taipei, Taiwan, dedicated to advancing health sciences and clinical research. Established with a focus on fostering innovation in medical education, TMU integrates comprehensive clinical training with rigorous research methodologies. The university is committed to improving patient outcomes through a strong emphasis on translational medicine and interdisciplinary collaboration. TMU's clinical trial initiatives are designed to explore new treatments and therapies, contributing to the global body of medical knowledge while adhering to the highest ethical standards and regulatory compliance.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taipei City, , Taiwan
New Taipei City, , Taiwan
Taipei City, , Taiwan
Patients applied
Trial Officials
Feng-Heng Chang, ScD
Principal Investigator
Graduate Institute of Injury Prevention and Control, Taipei Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported